3 completed, 2 not yet recruiting, 1 recruiting. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Not yet recruiting 2, Recruiting 1 |
| Phase 2 | 6 | Completed 3, Not yet recruiting 2, Recruiting 1 |
Follow Hearing Loss, Hidden: new trials by email Literature Review of Hearing Loss, Hidden trials Research Report on Hearing Loss, Hidden
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations CIL001 (Paliroden), Placebo - Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 135 | 2027-01-01 | 2026-10-26 |
| A Study Testing Safety and Efficacy of Transtympanic Paliroden for the Treatment of Cochlear Synaptopathy in Participants With Chronic, Constant Tinnitus paliroden (CIL001), Placebo - Tinnitus, Bilateral, Cochlear Synaptopathy | Phase 1 / Phase 2 | Not yet recruiting | Cilcare SAS | 60 | 2027-01-01 | 2026-09-17 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients NS101, Placebo - Seneorineural Deafness, Sudden Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Neuracle Science Co., LTD. | 113 | 2024-02-15 | 2026-11-02 |
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss PIPE-505, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Contineum Therapeutics | 28 | 2020-10-15 | 2025-04-01 |
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment OTO-413, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 110 | 2019-10-01 | 2022-10-27 |
Hearing Loss, Sensorineural (4) · Hearing Loss (3) · Auditory Diseases, Central (1) · Deafness (1) · Diabetes Mellitus (1) · Hearing Disorders (1) · Hearing Loss, Noise-Induced (1) · Hearing Loss, Sudden (1) · Language Development Disorders (1) · Presbycusis (1) · Tinnitus (1)
Ear Diseases (6) · Nervous System Diseases (6) · Neurologic Manifestations (6) · Otorhinolaryngologic Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Sensation Disorders (6) · Signs and Symptoms (6) · Hearing Disorders (5) · Hearing Loss (3) · Brain Diseases (1) · Central Nervous System Diseases (1) · Communication Disorders (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Language Disorders (1)
Clemastine (1) · Placebo Effect (1)
Cilcare SAS (2) · Contineum Therapeutics (1) · Neuracle Science Co., LTD. (1) · Otonomy, Inc. (1) · University of Colorado, Denver (1)
United States (3) · South Korea (1)
Achim Klug, PhD (1) · Joseph Park, M.D. (1) · Samuel A Budoff, PhD, MS (1) · Stephen Huhn, MD (1)
2025 (1)